Ortho-Clinical Diagnostics Vitros ECi
This article was originally published in The Gray Sheet
Executive Summary
Test menu for fully-automated, random-access immunodiagnostic system includes anti-hepatitis B core (anti-HBc) and anti-HBc IgM assays to aid in diagnosing hepatitis B, following recent PMA approval. The two additions to the system complement three previously approved hepatitis assays - anti-HBs, HBsAg and anti-HCV. The Johnson & Johnson subsidiary debuted its Vitros anti-HAV total assay on the ECi system outside the U.S. in December. Anti-HIV 1+2 assay U.S. trials are "nearly complete," and the firm plans 510(k) submissions later this year for IgM and IgG assays for toxoplasma, rubella and CMV...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.